ANTRENYL Drug Patent Profile
✉ Email this page to a colleague
When do Antrenyl patents expire, and what generic alternatives are available?
Antrenyl is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ANTRENYL is oxyphenonium bromide. Additional details are available on the oxyphenonium bromide profile page.
Summary for ANTRENYL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 46 |
Patent Applications: | 743 |
DailyMed Link: | ANTRENYL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ANTRENYL
US Patents and Regulatory Information for ANTRENYL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | ANTRENYL | oxyphenonium bromide | TABLET;ORAL | 008492-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |